Xofigo
Xofigo is the brand name for radium-223 dichloride, a radiopharmaceutical used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastases and no known visceral metastases. It was developed by Algeta and marketed by Bayer. In the United States, Xofigo received FDA approval in 2013 and has since been approved in several other regions, with labeling that specifies its use for patients with bone-dominant disease.
Xofigo works as an alpha-emitting radiopharmaceutical. Radium-223 behaves similarly to calcium and tends to localize to
Administration of Xofigo is via intravenous injection at a dose of 55 kilobecquerels per kilogram of body
Common adverse effects reported during Xofigo treatment include diarrhea, nausea, vomiting, and hematologic events such as
Xofigo provides a targeted option for men with symptomatic bone metastases from mCRPC and no known visceral